Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC),
with programmed cell death ligand 1 (PD-L1) expression associated with improved …

Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …

Background Clinical trial data have shown that among breast cancer patients who were
disease free after 5 years of adjuvant treatment with tamoxifen, further extended treatment with …

Background For postmenopausal women with hormone-receptor–positive breast cancer,
the most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear. …

Background Patients with human epidermal growth factor receptor 2 (HER2)–positive
metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted …

Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown
superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic …

Background Patient outcomes are poor for aggressive B-cell non-Hodgkin’s lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …

Background Whether it is possible to reduce the intensity of treatment in early (stage I or II)
Hodgkin's lymphoma with a favorable prognosis remains unclear. We therefore conducted a …

Purpose: According to current guidelines, molecular tests predicting the outcome of breast
cancer patients can be used to assist in making treatment decisions after consideration of …

Background The Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12)
bone substudy assesses zoledronic acid for preventing bone loss associated with adjuvant …